Sara wins the ASH abstract achievement award
Sara was awarded the ASH abstract achievement award of 2025. She joined the annual ASH meeting to give a talk about her most recent findings.
Sara was awarded the ASH abstract achievement award of 2025. She joined the annual ASH meeting to give a talk about her most recent findings.
Prof. Klusmann was elected chair of the AML-BFM study group. Here with he will be taking on this great resposibility of leading upcoming clinical trials.
Also this year the C3OMBAT-AML research teams get together to exchange findings and ideas. Thanking our sponsors of the Hilfe für krebskranke Kinder Frankfurt e. V., which fund us with over 1 Mio € yearly.
In this multicenter prospective trial, CPX-351 replaced conventional induction therapy aiming to reduce toxicity. This paper includes a retrospective analysis and future outlook.
Genomic and proteomic analyses identified critical dependencies, which with pharmacologic inhibition effectively induce apoptosis in NUP98::KDM5A AML models.
DLK1 was found to be a GATA1s-driven leukemia dependency in ML-DS, linking fetal hematopoietic programs to leukemic stemness and refractory disease.
This year the UCT Science day took place at the Goethe-University and our team contributed with numerous posters and talks. As usual an excellent event with inisghtful interdisciplinary exchange between Frankfurt and Marburg.
At this years Kind-Philipp-Meeting our team joined with a record breaking 21 talks. David was awarded the Kind-Philipp-Presentation Award for his excellent contribution.
We examined the relationship between the genetic and transcriptional evolution of ML-DS from natural variation using single cell sequencing.
We were honoured to film a segment with José Carerras and his team for his 30th charity gala. The clip was streamed along side others and celebrity guest acts, leading to a donation sum of over 3.5 Mio Euros.